Authors
Latest:
A Crossroads for the Digital Therapeutics Industry. Now is the Time to ActRecent events can provide digital therapeutics companies with clear lessons for the future.
Latest:
Why Machine Learning's Potential in Pharma Relies on Its TransparencyDespite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.
Latest:
Overcoming AI Bias Within Life SciencesHow to cultivate trust & connections in life sciences in a time of AI bias.
Latest:
Harnessing the Power of Communities to Combat Healthcare InequitiesBiopharma has a responsibility to meet patients where they are.
Latest:
To Reduce Commercial Risk for Orphan Drugs, Transform ForecastingTo successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Latest:
The Emergence of Commercial Health Insurances as an Access Route to the Chinese MarketCommercial Health Insurance may bring more opportunities for market access in China.
Latest:
AI’s Promise in Delivering on Patient-CentricityHow pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.
Latest:
Startup Launch Guide: Avoiding 10 Common Pain PointsWith opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.
Latest:
Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime ValuePresenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
Latest:
Three Key Steps to Unlocking mRNA’s Potential Beyond COVID-19Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.
Latest:
Digital Medicine and Pharma: The Partnerships Bringing Together Molecule and SoftwarePharmaceutical Executive, in collaboration with Biofourmis, organized a roundtable of experts from various groups to discuss how digital medicine and pharmaceuticals are changing the trajectory of what drug development and clinical care look like together, with an emphasis on partnerships within digital health.
Latest:
Transforming Healthcare Data to Precision MedicineA modern healthcare ecosystem involves various stakeholders and many forms of complex data. Collaborations and a range of advanced approaches are essential to providing more uniform and complete healthcare to patients.
Latest:
The future of life sciences and healthcare v2Genpact’s latest report, Life Sciences and Healthcare in the Age of Instinct, explores three major trends shaping the future of healthcare.
Latest:
No Half Measures: How Medical Affairs Can Maximize and Measure ValueEducation and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
Latest:
The Quest to Fully Address Prescription Drug AffordabilityThe Medicare Part D cap won’t solve need for financial assistance.
Latest:
The Rapid Growth of Remote Patient Monitoring Solutions Can Accelerate Decentralized Clinical TrialsPharma companies and RPM manufacturers must work together to find solutions to make DCT more commonly available.
Latest:
How Good is a Good Product Launch?A fresh look at how industry benchmarks can help fortify new drug launches to overcome today’s new market-entry barriers and higher expectations.
Latest:
Using GenAI as a Co-Pilot for Regulatory IntelligenceGenAI is on the precipice of breaking new ground in regulatory intelligence; making strategists more efficient by alleviating challenges, streamlining regulatory research and submission processes.
Latest:
Silver Linings of a Global Health Crisis: A New Path Forward for Pharma Media Professionalsat some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?
Latest:
Industry Predictions For 2023Top industry experts weigh in on what the new year holds for the pharma industry.
Latest:
Instead of Drug Spending Caps, Medicare Should Try Value-Based ContractingNew regulations may require regulators to explore new payment options.
Latest:
Precision & Specialty Medicine Clinical TrialsPrecision & Specialty Medicines are driving changes in the pharma development industry. We explore the changes these paradigms are having on the clinical trial space.
Latest:
Shining a Light on Rare Disease: Evidence Challenges and SolutionsSignificant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.
Latest:
Competing in Commercial Pharmaceuticals: Get Formal and Familiar with AnalyticsExploring the importance of analytics as a means of staying competitive in the commercial pharmaceutical market.
Latest:
Is Model Informed Drug Development Regulatory Pathway an Exception or the Norm?MIDD can pave new road for drug development.
Latest:
Four Critical Considerations for Launching Digital Diagnostic ToolsCreating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
